TX judges send Wyeth back to court; Health Canada criticized for "speeding up" approvals;

> Wyeth, the drugmaker being acquired by Pfizer, must face a lawsuit by a woman who claims her breast cancer was caused by the menopause medicine Prempro, a Texas appeals court ruled. Report

> A pharma industry critic says Health Canada puts too much emphasis on speeding up drug approvals and too little on following up on safety after drugs hit the market. Report

> Merrill Lynch cut its rating on AstraZeneca stock to "underperform" from "neutral" because of "relatively weaker long-term fundamentals." Report

> Pfizer invited investors and the public to tune in to a webcast of its annual shareholders meeting at 8:30 a.m. Thursday. Release

> Retail drug sales in India leapt by 18.4 percent in March after a 13.3 percent rise in February. Report

>Par Pharmaceutical said it resolved patent litigation with Reliant Pharmaceuticals with a settlement that allows Par to product a generic version of Reliant's Rhythmol product beginning in 2011. Release

> PricewaterhouseCoopers and the National Venture Capital Association have issued their quarterly report on the state of the venture capital market. Report

> Shares of Discovery Laboratories plunged today as the FDA announced that it wouldn't approve the company's drug Surfaxin for treatment of respiratory illness in infants. Report

> Pharmasset announced that the company has halted a late-stage study for its experimental chronic hepatitis B treatment clevudine. The news sent Pharmasset's shares tumbling nearly 14 percent in morning trading. Report

> With the public markets closed and venture funds in short supply, BIOTECanada is calling for more government support of the Canadian life science industry. Report

> Belgium's Galapagos says it's inked a deal with Merck in which Galapagos will use its SilenceSelect target discovery platform to identify inflammatory disease targets. Report

> The newly approved stimulus package includes $1.3 billion for cancer research in 2009 and 2010, and the head of the National Cancer Institute says that money will go a long way toward doubling the number of research grants that it approves. Report

> For years stem cell researchers have complained that federal guidelines limited the number of embryonic stem cell lines they could work with to a tiny selection. But all of that is about to change. Report

> A team of researchers at Cancer Research Technology says that a new drug that targets PKD in tumors has demonstrated a promising ability to target pancreatic and lung cancer. Report

And Finally... Next week, ex-FDA chief Dr. David Kessler premieres a book highlighting his research into "conditioned hypereating" of fatty, sugary foods. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.